Target species
Dogs and cats.
Indications for use for each target species
Dogs: For the treatment of infected wounds and abscesses, and infected mouth cavity and dental infections, caused by or associated with Staphylococcus spp., Streptococcus spp. (except Streptococcus faecalis), Bacteroides spp., Fusobacterium necrophorum, and Clostridium perfringens. To help provide antimicrobial cover during dental procedures.
For the treatment of superficial pyoderma associated with Staphylococcus intermedius.
For the treatment of osteomyelitis, caused by Staphylococcus aureus.
Cats: For the treatment of infected wounds and abscesses and infected mouth cavity and dental infections, caused by bacteria sensitive to clindamycin. To help provide antimicrobial cover during dental procedures.
Before therapy with the veterinary medicinal product is initiated, the involved pathogens should be identified and sensitivity to clindamycin established.
Contraindications
Do not use in animals which are hypersensitive to preparations containing clindamycin or lincomycin.
Do not administer to rabbits, hamsters, guinea pigs, chinchillas, horses, or ruminants because ingestion of clindamycin by these species may result in severe gastro-intestinal disturbance.
Special warnings
None.
Special precautions for use
Special precautions for safe use in the target species:
Clindamycin and erythromycin show parallel resistance. Partial cross-resistance has been demonstrated between clindamycin, erythromycin and other macrolides antibiotics.
During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed.
Animals with severe renal and/or very severe hepatic disturbances accompanied by severe metabolic aberrations should be dosed with caution and should be monitored by serum examination during high-dose clindamycin therapy.
Clindamycin sometimes causes the overgrowth of non-sensitive organisms such as resistant clostridia and yeasts. In cases of superinfection, appropriate measures must be taken according to the clinical situation.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Wash hands after handling capsules.
Special precautions for the protection of the environment:
Not applicable.
Adverse events
Dogs and cats:
Rare (1 to 10 animals / 10 000 animals treated): | Vomiting, Diarrhoea |
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Use during pregnancy, lactation or lay
Pregnancy and lactation:
The safety of the veterinary medicinal product has not been established during pregnancy or lactation. Use only according to the benefit-risk assessment by the responsible veterinarian.
Interaction with other medicinal products and other forms of interaction
Clindamycin hydrochloride has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. The veterinary medicinal product should be used with caution in animals receiving such agents.
Clindamycin should not be used concomitantly with chloramphenicol or macrolides as they antagonise each other at their site of action at the 50S ribosomal sub-unit.
Administration routes and dosage
Oral administration.
1. For the treatment of infected wounds and abscesses, and infected mouth cavity and dental infections in dogs and cats, administer either: |
| ∙ 5.5 mg/kg of bodyweight every 12 hours for 7-10 days, or |
| ∙ 11 mg/kg of bodyweight every 24 hours for 7-10 days. |
If no clinical response is seen within 4 days, redetermine the diagnosis. To help provide antimicrobial cover during dental procedures, a 10-day course is recommended. This should be initiated five days before dental therapy and continued for five days thereafter. In dogs, treatment may be extended to a maximum of 28 days based on clinical judgement.
2. For the treatment of superficial pyoderma in dogs, administer either: |
| ∙ 5.5 mg/kg of bodyweight every 12 hours, or |
| ∙ 11 mg/kg of bodyweight every 24 hours. |
Therapy of canine superficial pyoderma is usually recommended for 21 days, with extension of therapy based on clinical judgement.
3. For the treatment of osteomyelitis in dogs, administer: |
| ∙ 11 mg/kg of bodyweight every 12 hours for a minimum of 28 days. |
If no clinical response is seen within 14 days, the treatment should be stopped and the diagnosis redetermined.
Symptoms of overdose (and where applicable, emergency procedures and antidotes)
The maximum dosage which is well tolerated orally by dogs is 300 mg/kg bodyweight. This is 27 times the indicated dosage for the treatment of superficial pyoderma, infected wounds, abscesses, mouth cavity and dental infections.
Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance
Not applicable.
Withdrawal periods
Not applicable.